Hemodynamic and renal effects following bolus injection of atrial natriuretic peptide (α-hANP) in normal subjects

A rapid vacuum-driven procedure, using pre-treated Sep-Pak C18 cartridges, has been developed for the simultaneous extraction of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) from plasma. Non-specific interference was removed by fractional elution with an aqueous methanol/trifluoroacetic acid (TFA) mixture. AVP and ANP were coeluted under positive pressure with a methanol/TFA mixture and the eluates air-dried before measurement using separate radioimmunoassays. Assay ranges for AVP and ANP were 0·12–29·5 pmol/L and 0·65–162 pmol/L, respectively, with mean recoveries (standard deviation in parentheses) for AVP of 96·4% (5·5%) at a level of 11·8 pmol/L and for ANP of 94·8% (5·9%) at a level of 32·4 pmol/L. The extraction and assay procedures were validated by observing the changes in plasma AVP and ANP concentrations in normal subjects at different stages of hydration and in elderly patients during treatment for congestive cardiac failure.

Download Full-text

Immunoradiometric assay of atrial natriuretic peptide in unextracted plasma

Clinical Chemistry ◽

10.1093/clinchem/36.6.855 ◽

1990 ◽

Vol 36 (6) ◽

pp. 855-859 ◽

Cited By ~ 7

Author(s):

J E Tattersall ◽

A Dawnay ◽

C McLean ◽

W R Cattell

Keyword(s):

Atrial Natriuretic Peptide ◽

Natriuretic Peptide ◽

Normal Subjects ◽

Disulfide Bridge ◽

Immunoradiometric Assay ◽

Assay Sensitivity ◽

Standard Curve ◽

Hook Effect ◽

C Terminus ◽

Atrial Natriuretic

Abstract We have developed and validated a two-site liquid-phase immunoradiometric assay (IRMA) of atrial natriuretic peptide (ANP) in unextracted human plasma. Both radiolabeled rabbit anti-ANP IgG and polyclonal mouse anti-ANP must bind to ANP for detection, and the assay is specific for peptides with both an intact C-terminus and a disulfide bridge. The assay sensitivity (detection limit) is 0.96 pmol/L, and the working range is 2.3-300 pmol/L, with the hook effect occurring above 500 pmol/L. Results for diluted plasma from normal subjects and from patients with renal failure paralleled the standard curve; analytical recovery of ANP added to such samples averaged 94%. The between- and within-assay CVs at 8 pmol/L were 10% and 5%, respectively. The assay is sufficiently sensitive and precise to detect the postural change in ANP concentrations in normal subjects.

Download Full-text

Renal effects of atrial natriuretic peptide in a marine elasmobranch

AJP Regulatory Integrative and Comparative Physiology ◽

10.1152/ajpregu.1990.258.5.r1201 ◽

1990 ◽

Vol 258 (5) ◽

pp. R1201-R1206 ◽

Cited By ~ 5

Author(s):

S. Benyajati ◽

S. D. Yokota

Keyword(s):

Atrial Natriuretic Peptide ◽

Natriuretic Peptide ◽

Aortic Pressure ◽

Renal Effects ◽

Physiological Dose ◽

Excretion Rates ◽

Solute Excretion ◽

Mammalian Peptide ◽

Mean Aortic Pressure ◽

Atrial Natriuretic

The effects of atrial natriuretic peptide on the renal function of the spiny dogfish (Squalus acanthias) in seawater were evaluated. A synthetic mammalian peptide, atriopeptin II (2 micrograms/kg), was injected intravascularly into unanesthetized, unrestrained fish prepared for renal clearance studies. The aortic pressure, glomerular filtration rate (GFR), urine flow rate (V), and urinary excretion of sodium, potassium, and total osmolytes were continuously monitored. Atriopeptin II significantly decreased mean aortic pressure (-12%), GFR (-40%), V (-66%), and the absolute excretion rates of sodium (-47%), potassium (-43%), and total osmolytes (-44%). However, the renal effects of atriopeptin II were temporally dissociated from the vasodepressor effect. Mean aortic pressure decreased quickly and returned to control values approximately 2 h after injection, whereas GFR did not decrease significantly until the third hour after injection. The decreases in renal water and solute excretion in response to atriopeptin could be accounted for by the decrease in GFR, since there were no significant changes in fractional water or solute excretion. Similar decreases in GFR were observed during constant infusions of a lower physiological dose of the peptide (80 pg.kg-1.min-1). The observed antidiuretic and antinatriuretic effect of synthetic atriopeptin in the dogfish contrasts with its putative role as a hormone mediating hypervolemic regulation.

Download Full-text

The renal effects of atrial natriuretic peptide in man are not attenuated by (+)-sulpiride.

British Journal of Clinical Pharmacology ◽

10.1111/j.1365-2125.1989.tb05329.x ◽

1989 ◽

Vol 27 (1) ◽

pp. 13-18 ◽

Cited By ~ 12

Author(s):

S. Freestone ◽

TM MacDonald ◽

RF Jeffrey ◽

J. Brown ◽

MR Lee

Keyword(s):

Atrial Natriuretic Peptide ◽

Natriuretic Peptide ◽

Renal Effects ◽

Atrial Natriuretic

Download Full-text

THE RENAL EFFECTS OF CORTICOTROPIN-RELEASING HORMONE. IMPLICATION OF VASOPRESSIN AND ATRIAL NATRIURETIC PEPTIDE

Journal of Hypertension ◽

10.1097/00004872-200006001-00723 ◽

2000 ◽

Vol 18 ◽

pp. S205-S206

Author(s):

J. Gutkowska ◽

M. Jankowski ◽

S. Mukaddam-Daher ◽

S. M. McCann

Keyword(s):

Atrial Natriuretic Peptide ◽

Natriuretic Peptide ◽

Corticotropin Releasing Hormone ◽

Renal Effects ◽

Releasing Hormone ◽

Atrial Natriuretic

Download Full-text

Effect of atrial natriuretic peptide on catecholamine release from human pheochromocytoma

Acta Endocrinologica ◽

10.1530/acta.0.1200107 ◽

1989 ◽

Vol 120 (1) ◽

pp. 107-112 ◽

Cited By ~ 5

Author(s):

Mitsuaki Nakamaru ◽

Toshio Ogihara ◽

Hiroshi Saito ◽

Hiromi Rakugi ◽

Kiyoko Hashizume ◽

...

Keyword(s):

Atrial Natriuretic Peptide ◽

Natriuretic Peptide ◽

Direct Action ◽

Plasma Catecholamines ◽

Normal Subjects ◽

Catecholamine Release ◽

Plasma Norepinephrine ◽

Atrial Natriuretic

Abstract. The effect of synthetic alpha human atrial natriuretic peptide on catecholamine release from human pheochromocytomas was studied both in vivo and in vitro. Iv infusion of atrial natriuretic peptide at a rate of 0.1 μg ·kg−1·min−1 for 60 min into two normotensive patients with pheochromocytoma caused a small decrease in the mean blood pressure, increase in the heart rate, and marked increase in the plasma level of norepinephrine (2.08 to 6.83 nmol/l, and 1.15 to 2.83 nmol/l, respectively) compared with 0.60 ± 0.10 to 1.19 ± 0.20 nmol/l in normal subjects. Treatment with atrial natriuretic peptide also increased the plasma epinephrine level from 0.34 to 1.27 nmol/l, and from 0.67 to 0.79 nmol/l in the patients with pheochromocytoma, but not in the normal subjects (0.05 ± 0.01 to 0.05 ± 0.01 nmol/l). After removal of the tumour, the responses of the plasma norepinephrine and epinephrine to atrial natriuretic peptide infusion were normalized. There was no significant effect of 10−8 to 10−5 mol/l atrial natriuretic peptide on the basal release of catecholamines from isolated superfused pheochromocytoma tissue. Atrial natriuretic peptide (10−7 mol/l) did not affect the increase in catecholamine release induced by glucagon (10−5 mol/l). These results suggest that the exaggerated responses of plasma catecholamines to atrial natriuretic peptide in patients with pheochromocytoma may be due to a washout effect resulting from change in blood flow in the vessels feeding the tumour rather than increased sympathetic nerve activity induced by hypotension and hypovolemia. The results also suggest that atrial natriuretic peptide dose not have any direct action on pheochromocytoma tissue causing catecholamine release.

Download Full-text